PARK CITY, Utah — Outcomes from the phase 1/2a HORNBILL study indicate a potential disease-modifying effect of BI 764524 in eyes with diabetic macular ischemia.
Regarding safety, single and multiple intravitreal injection doses were well tolerated, Quan Dong Nguyen, MD, MSc, said at Clinical Trials at the Summit.
Currently, no approved treatment is available for diabetic macular ischemia (DMI). BI 764524 (Boehringer Ingelheim) is an investigational drug targeting semaphorin 3A (Sema3A), a complex molecule involved in the processes of dysregulation of angiogenesis and increased retinal